HIỆU QUẢ ĐIỀU TRỊ BẰNG PHỐI HỢP EMPAGLIFLOZIN Ở BỆNH NHÂN CAO TUỔI SUY TIM MẠN CÓ PHÂN SUẤT TỐNG MÁU GIẢM NHẸ TẠI BỆNH VIỆN ĐA KHOA TỈNH SÓC TRĂNG

Abstract

Objective: Evaluating the effectiveness of treatment with Empagliflozin combination in elderly patients with chronic heart failure with mildly reduced ejection fraction at Soc Trang Provincial General Hospital in 2023 - 2024. Subjects and methods: Research Cross-sectional descriptive study of 127 elderly patients with chronic heart failure with mildly reduced ejection fraction at Soc Trang Provincial General Hospital in 2023 - 2024. Results: The proportion of women in this age group is larger than that of males (65.4% compared to 34.6%); the age group includes a significant number of those aged 70-79 (39.4%). BNP (532.6 ± 653.2 pg/mL dropped to 109.2 ± 249.8 pg/mL) following three months of combined therapy with empagliflozin; LVEF (45.5 ± 2.9% rose to 56.2 ± 8.5%). The mortality rates were 0.8%, 0.8%, 0.8%, and the rehospitalization rates were 8.7%, 5.5%, 2.4% at the first, second, and third months. Men were readmitted at a greater rate than women within three months, according to the Kaplan-Meier curve (p = 0.08). Conclusion: Combining Empagliflozin in the treatment of heart failure with mildly reduced ejection fraction in elderly patients helps improve clinical symptoms of heart failure, BNP, LVEF, readmission without any severe side effects within 3 months.